Qurient Quarterly Report: Pipeline Progress and Financial Stability

Telacebec (Q203) showed 100% cure rate in Buruli ulcer Phase 2a in Australia; US FDA Priority Review Voucher (PRV) virtually assured (current trading ~$200M)
Mocaciclib (Q901) completed dose escalation in Phase 1 with high safety (no toxicity up to 90mg/m2); combo with MSD/Keytruda and NCI collaboration for SCLC ongoing
QP101 dual-payload ADC shows superior efficacy in T-DXd resistant models in preclinical; Synaffix license deal ($249.5M total)
Adrixetinib (Q702): cGvHD Phase 1b IND approved in Spain; AML trial with MD Anderson; exploring biomarkers for Keytruda combo
Consolidated quarterly revenue: 1.94B KRW (distribution); operating loss: 7.67B KRW (R&D 5.39B, R&D/revenue 308%)
Cash and cash equivalents: 9.48B KRW; raised funds via 3rd/4th BW/CB (9B/12.8B KRW each), but potential dilution risk
Credit rating: BB0 (SCI, 2023); continued losses but exempt from management listing criteria due to innovative pharma certification

ADVERTISEMENT (250px+)